无锡贝塔融资破亿，推动碳-14全产业链建设及碳-14核电池产业化

Group 1: Company Overview - Wuxi Beta Pharmaceutical Technology Co., Ltd. announced the completion of a strategic financing round worth hundreds of millions of yuan on October 20, with funds primarily allocated for the development of a global leading C-14 industry chain and the "Zhulong" series of C-14 nuclear batteries [1] - Founded in November 2008 by Dr. Li Gang, Wuxi Beta is the first high-tech enterprise in China specializing in the development and application of C-14 isotope technology [6] - The company aims to become a leading enterprise in the C-14 field in China and an international leader in C-14 technology, focusing on a comprehensive C-14 industry chain [6][9] Group 2: Strategic Investment - Renowned entrepreneur Chen Zemin, founder of Sanquan Foods, has joined Wuxi Beta as a strategic investor and will serve as the honorary chairman and president [1][10] - Chen Zemin's investment represents his third entrepreneurial venture, emphasizing his commitment to advancing cutting-edge technology and contributing to national strategic security and industrial upgrades [10][14] Group 3: Technological Development - Wuxi Beta has developed a complete C-14 industry chain technology system, including irradiation target materials, separation and purification, C-14 source materials, and C-14 products [6][9] - The company has successfully achieved the domestic production of C-14 source materials in collaboration with the China Nuclear Power Research and Design Institute, breaking the reliance on imports [8][9] - The "Zhulong No. 1" C-14 nuclear battery prototype was launched in March 2025, marking a significant milestone in the company's technological advancements [10] Group 4: Future Prospects - Wuxi Beta is currently progressing with the development of the "Zhulong No. 2" C-14 nuclear battery, with successful cold tests and ongoing optimization of thermal testing processes [12] - The company has established a wholly-owned subsidiary to accelerate the iteration and industrialization of C-14 nuclear batteries, while also preparing for the necessary regulatory approvals and facility constructions [12][14]